Global Veterinary Anti-Infective Market projected to grow to $7.47 billion by 2034

From GlobeNewswire: 2024-07-05 05:47:00

The global Veterinary Anti-Infective Market is projected to grow from US$ 5.03 billion in 2024 to US$ 7.47 billion by 2034, with a 4% CAGR. Key drivers include the rising incidence of foodborne and zoonotic illnesses, pet health concerns, and increased pet adoption. The United States, Brazil, and Chile are key market players in Latin America. Leading industry participants include Neogen Corporation, Zoetis, Inc., and Vetoquinol S.A.

The rise in foodborne infections originating from animals is a significant concern, leading to increased demand for veterinary anti-infective medications. Government initiatives promoting veterinary health services contribute to market growth. Elanco Animal Health introduced the drug Increxxa for cattle respiratory disease, utilizing tularathromycin to effectively combat lung infections.

The Veterinary Anti-Infective industry is witnessing innovation from key players such as Sanofi, Virbac S.A., and Boehringer Ingelheim GmbH. The market is segmented based on species, drug class, mode of administration, and distribution channels across major regions. Fact.MR provides unbiased analysis and forecasts for the market from 2019 to 2034, offering valuable insights for stakeholders in the industry.

Various segments within the veterinary healthcare market are experiencing steady growth and are expected to reach significant valuations by 2034. From Veterinary Artificial Insemination to Antibiotic Residue Test Kits, Rapid Oral Fluid Screening Devices, and more, the industry is evolving to meet the rising demand for premium animal healthcare services. With a focus on innovation and regulation compliance, industry players are driving advancements in veterinary anti-infectives to ensure the well-being of animals and the safety of food products.



Read more at GlobeNewswire: Veterinary Anti-Infective Market to Hit US$ 7.47 Billion by